Cellectar Biosciences, Inc. (CLRB): restructuring charge — Cellectar pivots away from iopofosine I 131 accelerated approval; cuts workforce 60%

Cellectar Biosciences, Inc.

Due to FDA Type-C meeting, accelerated approval for iopofosine I 131 would now require randomized confirmatory study with PFS endpoint; company seeking strategic options for this program.
Workforce cut ~60%; expects annual operating cost savings of ~$7.5M and ~$1.7M severance costs in Q4 2024/Q1 2025.
Shifting focus to alpha- (CLR 121225) and Auger-emitter (CLR 121125) programs; expects to file IND applications in H1 2025 for Phase 1 solid tumor studies.
Restructuring expected to extend cash runway into Q3 2025 from earlier depletion estimate.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Cellectar Biosciences, Inc. announced a restructuring with charges of approximately $1.7 million affecting overall workforce (approximately 60%).

Type: restructuring
Charge: approximately $1.7 million
Affected area: overall workforce
Headcount: approximately 60%

Exact text from the filing

will decrease its annual operating costs by approximately $7.5 million. Additionally, the Company estimates that it will incur aggregate severance costs of approximately $1.7 million, which will be recorded primarily in the fourth quarter of 2024 and first quarter of 2025. The cost that the Company expects to incur in connection with the workforce reduction

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-127487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.